The first patient has been treated using NorthStar Medical Radioisotopes' electron accelerator-generated copper-67 (Cu-67) radioisotope in Clarity Pharmaceutical's U.S.-based SARTATE peptide receptor radionuclide therapy trial.
The phase I/IIa trial is investigating the use of copper-64 (Cu-64) and copper-67 (Cu-67) for treatment of neuroblastoma and neuroendocrine tumors.
